Αποτελέσματα Αναζήτησης
1 Μαΐ 2018 · Dose-Dense AC + TH is often given with the goal of cure and administered either before surgery (neoadjuvant therapy) to shrink the size of the tumor, or after surgery (adjuvant therapy) to kill any cancer cells that may be still present in the body.
This treatment regimen consists of two parts: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Breast neoadjuvant/adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly. Breast adjuvant TH (DOCEtaxel and trastuzumab) three weekly.
23 Σεπ 2021 · At 26 weeks, 33%–90% of patients treated with TZP achieved the HbA1c target <7% versus (vs) 52% with dulaglutide and 12% with placebo. At 26 weeks, changes in mean body weight ranged from −0.9 to −11.3 kg for TZP versus −0.4 kg for placebo versus −2.7 kg for dulaglutide.
26 Απρ 2016 · Docetaxel plus cyclophosphamide (TC) × 4 is recommended as an alternative to AC × 4 and offers improved disease-free survival (DFS) and overall survival (OS). Classic CMF with oral cyclophosphamide for six cycles is another option.
This protocol is part of the AC-TH regimen: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Link to Breast adjuvant AC-TH overview; Link to Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly; Drug status: Docetaxel is on the PBS general schedule. Trastuzumab is PBS authority
6 Οκτ 2011 · Background. Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac...
31 Ιουλ 2017 · The two most commonly used regimens in the United States are ACTH (doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab) and TCH (docetaxel, carboplatin, and...
